AH23848 hemicalcium salt
Based on 1 publication(s) in Google Scholar
AH23848 hemicalcium salt is an orally active, selective competitive blocker of the thromboxane A2 receptor, with an IC50 value of 50 nM. AH23848 hemicalcium salt shows no activity against other prostaglandin, serotonin (5-HT) or adenosine diphosphate (ADP) receptors. AH23848 hemicalcium salt can be used in the research of occlusive vascular diseases.
For research use only. We do not sell to patients.
- Purity: 97.0%
- CAS No.: 81496-19-7
- Formula: C29H34NO5.1/2Ca
- Molecular Weight:496.62
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Orally Active Compound Library
HY-L061
-
Angiogenesis-Related Compound Library
HY-L088
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) AH23848 hemicalcium salt
More
Biological Activity
Thromboxane Receptor[1]
AH23848 (compound 6) (3.0×10-8-3.0×10-6 mol/liter; 30 min) hemicalcium salt acts as a competitive antagonist of thromboxane A2 receptors in isolated human pulmonary artery smooth muscle with a pA2 of 7.8[1].
AH23848 (6.0×10-8-6.0×10-6 mol/liter; 1.0×10-5 mol/liter) hemicalcium salt competitively antagonizes thromboxane A2 receptors in isolated rat aorta smooth muscle with a pA2 of 7.94, and does not block 5-HT or potassium chloride-induced contractions at concentrations up to 1.0×10-5 mol/liter[1].
AH23848 (1.0×10−6 mol/liter) hemicalcium salt does not block PGE2- or PGF2α-induced contractions in isolated non-vascular smooth muscle preparations[1].
AH23848 (1.0×10-7-1.0×10-4 mol/liter) hemicalcium salt potently and specifically inhibits thromboxane receptor-dependent platelet aggregation in human platelet-rich plasma, with IC50 values ranging from 1.05×10-7 to 6.3×10-7 mol/liter for different agonists, and does not block ADP-, 5-HT-, or epinephrine-induced aggregation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
AH23848 (0.01-0.3 mg/kg; i.v.; single bolus) hemicalcium salt specifically antagonizes U-46619-induced mesenteric vasoconstriction in anesthetized Beagle dogs without altering baseline hemodynamic parameters[1].
AH23848 (1 mg/kg; p.o.; single dose) hemicalcium salt produces sustained, specific inhibition of collagen-induced platelet aggregation in conscious Beagle dogs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Guinea pig (anesthetized)[1]
-
Dosage:0.03 mg/kg (collagen-induced responses); 1.0 mg/kg (ADP-induced thrombocytopenia)
-
Administration:i.v.; single bolus
-
Result:Substantially reduced collagen-induced thrombocytopenia.
Almost completely abolished the collagen-induced diastolic pressor response.
Nearly eliminated collagen-induced bronchoconstriction.
Showed no inhibitory effect on ADP-induced thrombocytopenia at 1.0 mg/kg.
-
Animal Model:Beagle dog (anesthetized)[1]
-
Dosage:0.01-0.3 mg/kg
-
Administration:i.v.; single bolus
-
Result:Had little or no effect on baseline blood pressure or mesenteric arterial blood flow.
Specifically antagonized U-46619-induced mesenteric vasoconstriction.
Produced a mean 6.5-fold rightward shift in the U-46619 dose-effect curve at 0.1 mg/kg.
-
Animal Model:Beagle dog (conscious)[1]
-
Dosage:1 mg/kg
-
Administration:p.o.; single dose
-
Result:Produced a marked inhibition of collagen-induced platelet aggregation ex vivo, with a mean peak 23-fold rightward shift of the collagen concentration-aggregation curve.
Showed a residual twofold rightward shift still evident 11 hours after dosing.
Had no inhibitory effect on ADP-induced platelet aggregation ex vivo.
Chemical Information
-
CAS No. 81496-19-7
-
Appearance Solid
-
Molecular Weight 496.62
-
Formula C29H34NO5.1/2Ca
-
Color White to off-white
-
SMILES
O=C([O-])CC/C=C\CC[C@@H]1[C@@H](N2CCOCC2)C(C[C@@H]1OCC3=CC=C(C4=CC=CC=C4)C=C3)=O.[1/2 Ca2+]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Andrology
Cellular mechanism underlying leptin-induced anion secretion of rat epididymal epithelial cells. [Abstract]2024 May 22. PMID: 38778669
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz